Joerg Herrmann
#162,029
Most Influential Person Now
Researcher
Joerg Herrmann's AcademicInfluence.com Rankings
Joerg Herrmanncomputer-science Degrees
Computer Science
#9404
World Rank
#9878
Historical Rank
Computational Linguistics
#2265
World Rank
#2288
Historical Rank
Machine Learning
#4105
World Rank
#4154
Historical Rank
Artificial Intelligence
#4445
World Rank
#4506
Historical Rank
Download Badge
Computer Science
Joerg Herrmann's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Joerg Herrmann Influential?
(Suggest an Edit or Addition)Joerg Herrmann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. (2020) (427)
- Ubiquitin and ubiquitin-like proteins in protein regulation. (2007) (333)
- Peri-procedural myocardial injury: 2005 update. (2005) (330)
- Evaluation and management of patients with heart disease and cancer: cardio-oncology. (2014) (288)
- Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. (2001) (238)
- Simvastatin Preserves the Structure of Coronary Adventitial Vasa Vasorum in Experimental Hypercholesterolemia Independent of Lipid Lowering (2002) (227)
- 5-fluorouracil and cardiotoxicity: a review (2018) (221)
- Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue (2016) (214)
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia (2020) (204)
- Coronary microvascular dysfunction in the clinical setting: from mystery to reality. (2012) (193)
- Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. (2015) (185)
- Glycolytic Stimulation Is Not a Requirement for M2 Macrophage Differentiation. (2018) (182)
- Preprocedural Statin Medication Reduces the Extent of Periprocedural Non–Q-Wave Myocardial Infarction (2002) (170)
- The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. (2004) (166)
- Enhanced Expression of Lp-PLA2 and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques (2008) (165)
- Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. (2013) (157)
- Stabilisation of atherosclerotic plaques (2011) (154)
- Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both? (2007) (153)
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). (2022) (144)
- Nonsurgical retrieval of embolized coronary stents (2000) (140)
- SCAI expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologıa Intervencionista) (2016) (128)
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). (2022) (128)
- Interferon Gamma Induces Reversible Metabolic Reprogramming of M1 Macrophages to Sustain Cell Viability and Pro-Inflammatory Activity (2018) (127)
- Abnormal Coronary Flow Velocity Reserve After Coronary Intervention Is Associated With Cardiac Marker Elevation (2001) (126)
- Angiogenesis in Atherogenesis (2006) (124)
- Antioxidant intervention blunts renal injury in experimental renovascular disease. (2004) (121)
- Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events (2018) (116)
- SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio‐oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista) (2016) (114)
- Dysregulation of the Ubiquitin-Proteasome System in Human Carotid Atherosclerosis (2006) (113)
- Cardio-Oncology: Vascular and Metabolic Perspectives A Scientific Statement From the American Heart Association (2019) (111)
- Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis (2019) (110)
- Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis (2007) (107)
- Stabilization of atherosclerotic plaques: an update. (2013) (104)
- Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography. (2013) (103)
- Cardiotoxicity with vascular endothelial growth factor inhibitor therapy (2018) (102)
- Myocardial bridging. (2005) (97)
- The endothelium: Dysfunction and beyond (2001) (93)
- Circulating humanin levels are associated with preserved coronary endothelial function. (2013) (92)
- Cardiac tumors: echo assessment (2016) (91)
- Hypercholesterolemia and Hypertension Have Synergistic Deleterious Effects on Coronary Endothelial Function (2003) (85)
- The ubiquitin-proteasome system and cardiovascular disease. (2012) (78)
- Beneficial Effects of Antioxidant Vitamins on the Stenotic Kidney (2003) (77)
- Systems biology approaches to adverse drug effects: the example of cardio-oncology (2015) (77)
- Myocardial bridging is associated with alteration in coronary vasoreactivity. (2004) (76)
- Adventitial vasa vasorum heterogeneity among different vascular beds. (2004) (76)
- Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population. (2019) (74)
- Myocardial infarction due to percutaneous coronary intervention. (2011) (73)
- Vascular toxic effects of cancer therapies (2020) (73)
- Potential embolization by atherosclerotic debris dislodged from aortic wall during cardiac catheterization:: Histological and clinical findings in 7,621 patients (2000) (71)
- Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women (2017) (71)
- Differential Effect of Experimental Hypertension and Hypercholesterolemia on Adventitial Remodeling (2004) (68)
- Potential role of the ubiquitin-proteasome system in atherosclerosis: aspects of a protein quality disease. (2008) (66)
- Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. (2009) (63)
- Primary proteasome inhibition results in cardiac dysfunction (2013) (63)
- Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition (2017) (59)
- Oxidative stress‐related increase in ubiquitination in early coronary atherogenesis (2003) (57)
- Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes. (2002) (57)
- Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. (2003) (56)
- Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. (2018) (56)
- Cancer History Portends Worse Acute and Long-term Noncardiac (but Not Cardiac) Mortality After Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. (2016) (54)
- On to the road to degradation: atherosclerosis and the proteasome. (2010) (52)
- C-Reactive Protein Relaxes Human Vessels In Vitro (2002) (52)
- Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic (2020) (50)
- Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). (2014) (48)
- An update on cardio-oncology. (2014) (48)
- Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. (2005) (48)
- Proliferation of Coronary Adventitial Vasa Vasorum in Patients With Spontaneous Coronary Artery Dissection. (2016) (47)
- Arterial Thrombosis in Patients with Cancer (2018) (47)
- Differential distribution of vasa vasorum in different vascular beds in humans. (2008) (44)
- The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. (2015) (42)
- c-Myc Oncoprotein: Cell Cycle-Related Events and New Therapeutic Challenges in Cancer and Cardiovascular Diseases (2003) (42)
- Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. (2002) (41)
- Role of lipoprotein-associated phospholipase A2 in atherosclerosis (2008) (41)
- Humanin, a Cytoprotective Peptide, Is Expressed in Carotid Artherosclerotic Plaques in Humans (2012) (41)
- The potential clinical relevance of visible particles in parenteral drugs. (2012) (40)
- Cardio-oncology: role of echocardiography. (2014) (40)
- Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer (2018) (39)
- Hypertension exacerbates the effect of hypercholesterolemia on the myocardial microvasculature. (2003) (39)
- Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic (2016) (39)
- How to Develop a Cardio-Oncology Clinic. (2017) (37)
- Assessment of peripheral endothelial function predicts future risk of solid-tumor cancer (2020) (36)
- SCAI expert consensus statement-executive summary evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (2015) (36)
- Experimental hypercholesterolemia differentially affects adventitial vasa vasorum and vessel structure of the left internal thoracic and coronary arteries. (2005) (35)
- Phase‐contrast MRI‐based elastography technique detects early hypertensive changes in ex vivo porcine aortic wall (2009) (34)
- Sex-Related Differences in Fractional Flow Reserve–Guided Treatment (2013) (34)
- Exercise Training and Cardiovascular Health in Cancer Patients (2018) (34)
- Proceedings From the Global Cardio-Oncology Summit (2019) (33)
- Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction (2018) (33)
- Burden of Cardiac Arrhythmias in Patients With Anthracycline-Related Cardiomyopathy. (2017) (33)
- Tyrosine Kinase Inhibitors and Vascular Toxicity: Impetus for a Classification System? (2016) (32)
- The Association between Circulating MicroRNA Levels and Coronary Endothelial Function (2014) (32)
- Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. (2021) (31)
- Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease. (2015) (30)
- Cardio-Oncology Education and Training: JACC Council Perspectives. (2020) (28)
- Outcomes of Patients With Severe Symptomatic Aortic Valve Stenosis After Chest Radiation: Transcatheter Versus Surgical Aortic Valve Replacement (2019) (28)
- Arterial events in cancer patients-the case of acute coronary thrombosis. (2018) (28)
- Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors (2017) (28)
- Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge. (2020) (27)
- From trends to transformation: where cardio-oncology is to make a difference. (2019) (27)
- Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement (2020) (25)
- Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients (2021) (24)
- High‐sensitivity C‐reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non‐obstructive coronary artery disease (2017) (23)
- Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes. (2019) (23)
- Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy. (2013) (23)
- atg7-Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity (2021) (22)
- Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors (2020) (22)
- Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. (2011) (22)
- The Endothelium – the Cardiovascular Health Barometer (2008) (22)
- Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems‐Based Approaches (2016) (22)
- Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes (2020) (21)
- Relation between fractional flow reserve value of coronary lesions with deferred revascularization and cardiovascular outcomes in non-diabetic and diabetic patients. (2016) (21)
- Utility and Challenges of an Early Invasive Strategy in Patients Resuscitated From Out-of-Hospital Cardiac Arrest. (2019) (21)
- Percutaneous revascularization in patients treated with thoracic radiation for cancer (2017) (21)
- Inflammasome-Driven Interleukin-1α and Interleukin-1β Production in Atherosclerotic Plaques Relates to Hyperlipidemia and Plaque Complexity (2019) (20)
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity (2020) (20)
- Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer (2017) (19)
- Fractional flow reserve with dobutamine challenge and coronary microvascular endothelial dysfunction in symptomatic myocardial bridging. (2014) (18)
- Defining the Optimal Cardiac Troponin T Threshold for Predicting Death Caused by Periprocedural Myocardial Infarction After Percutaneous Coronary Intervention (2014) (18)
- Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey (2020) (17)
- Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors (2020) (16)
- Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer (2021) (16)
- Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans (2018) (15)
- Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients (2017) (15)
- Atherosclerosis in the back yard. (2007) (14)
- Vascular Toxicities of Cancer Therapies (2016) (14)
- Early Changes in 2D-Speckle-Tracking Echocardiography May Predict a Decrease in Left Ventricular Ejection Fraction inLymphoma Patients Undergoing Anthracycline Chemotherapy: A Pilot Study (2015) (14)
- Applications of Cardiac Computed Tomography in the Cardio-Oncology Population (2019) (14)
- Percutaneous transluminal laser guide wire recanalization of chronic subclavian artery occlusion in symptomatic coronary‐subclavian steal syndrome (2000) (14)
- High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice (2012) (13)
- Microvascular obstruction in non-infarct related coronary arteries is an independent predictor of major adverse cardiovascular events in patients with ST segment-elevation myocardial infarction. (2018) (13)
- Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single‐center analysis (2020) (13)
- SCAI Expert Consensus Statement (2016) (12)
- Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy (2021) (12)
- Cancer Patients Have a Higher Risk of Thrombotic and Ischemic Events After Percutaneous Coronary Intervention. (2021) (12)
- Cardio-oncology: an ongoing evolution. (2015) (12)
- New-onset heart failure in association with severe hypertension during trastuzumab therapy. (2014) (11)
- Association between coronary microvascular function and the vasa vasorum in patients with early coronary artery disease. (2016) (11)
- Should vascular effects of newer treatments be addressed more completely? (2015) (10)
- Coronary Disease Surveillance in the Community: Angiography and Revascularization (2020) (10)
- Corrigendum to: “The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extended” [Cardiovasc. Res. 61 (2004) 11–21] (2004) (10)
- Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy (2020) (10)
- Coronary artery bypass grafting in patients treated with thoracic radiation: a case–control study (2018) (10)
- Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies (2022) (9)
- In Search of a Less Invasive Approach to Cardiac Tumor Diagnosis: Multimodality Imaging Assessment and Biopsy. (2018) (9)
- Complicated and Advanced Atherosclerosis in a Young Woman With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Success and Challenges of BCR/ABL1-Targeted Cancer Therapy. (2015) (9)
- Impact of Cancer and Cardiovascular Disease on In-Hospital Outcomes of COVID-19 Patients: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry (2021) (9)
- The ubiquitin‐proteasome system—micro target for macro intervention? (2005) (9)
- Impact of cancer and cardiovascular disease on in-hospital outcomes of COVID-19 patients: results from the american heart association COVID-19 cardiovascular disease registry (2021) (9)
- Cardiovascular Health during and after Cancer Therapy (2020) (8)
- Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation (2021) (7)
- Response by Herrmann et al to Letter Regarding Article, "Vascular Toxicities of Cancer Therapies: The Old and the New-An Evolving Avenue". (2016) (7)
- Correction: Humanin, a Cytoprotective Peptide, Is Expressed in Carotid Artherosclerotic Plaques in Humans (2012) (7)
- Building a Cardio-Onco-Hematology Program (2018) (7)
- Renin inhibition with aliskiren lowers circulating endothelial progenitor cells in patients with early atherosclerosis. (2013) (7)
- Comparison of Complications and In-Hospital Mortality in Takotsubo (Apical Ballooning/Stress) Cardiomyopathy Versus Acute Myocardial Infarction. (2020) (7)
- Use of fractional flow reserve in patients with coronary artery disease: The right choice for the right outcome. (2017) (6)
- TWO DIMENSIONAL SPECKLE TRACKING ECHOCARDIOGRAPHY PREDICTS PRECLINICAL CARDIOTOXICITY IN BREAST CANCER PATIENTS (2014) (6)
- Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography (2022) (6)
- Electrocardiogram-gated Computed Tomography with Coronary Angiography for Cardiac Substructure Delineation and Sparing in Patients with Mediastinal Lymphomas Treated with Radiotherapy. (2019) (6)
- Improved Detection and Analysis of Sensed and Paced Events in Dual Chamber Pacemakers with Extended Memory Function A Prospective Multicenter Trial in 626 Patients (2001) (6)
- Spontaneous coronary artery dissection during hematopoietic stem cell infusion. (2013) (6)
- Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010 (2023) (5)
- Coronary Artery Disease: Development and Progression (2012) (5)
- Common Vascular Toxicities of Cancer Therapies. (2019) (5)
- Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography (2019) (5)
- Reducing Heart Dose with Protons and Cardiac Substructure Sparing for Mediastinal Lymphoma Treatment (2020) (5)
- Reaching Across the Aisle: Cardio-Oncology Advocacy and Program Building (2021) (5)
- TAVR in Cancer Patients: Comprehensive Review, Meta-Analysis, and Meta-Regression (2021) (5)
- N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors (2021) (4)
- Cardio-Oncology: Learning From the Old, Applying to the New (2020) (4)
- Leave me alone: the right ventricle in anterior myocardial infarction. (2010) (4)
- A New Temporary Occlusion and Aspiration System for Prevention of Distal Embolization During Percutaneous Transluminal Renal Angioplasty (2000) (4)
- Simply say yes to NO? Nitric oxide (NO) sensor-based assessment of coronary endothelial function. (2010) (4)
- Endothelial function under pressure. (2003) (4)
- Cardiovascular Toxicity With Cisplatin in Patients With Testicular Cancer (2020) (3)
- 2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors? (2022) (3)
- Coronary Stent Healing in Cancer Patients—An Optical Coherence Tomography Perspective (2021) (3)
- SHORT AND LONG TERM RISK OF CONGESTIVE HEART FAILURE IN BREAST CANCER AND LYMPHOMA PATIENTS COMPARED TO CONTROLS: AN EPIDEMIOLOGIC STUDY (2018) (3)
- THE IMMUNOPROTEASOME – A NEW CHARACTERISTIC OF SYMPTOMATIC CAROTID ARTERY PLAQUES (2012) (3)
- Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era (2021) (3)
- Should the 'echo guidelines' be followed in cancer patients? (2015) (2)
- Clinical genetics and pediatric neoplasms: pathogenetic and etiologic perspectives. (1979) (2)
- HIGH SENSITIVITY C REACTIVE PROTEIN IS AN INDEPENDENT MARKER OF CORONARY ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH NONOBSTRUCTIVE CORONARY ARTERY DISEASE (2016) (2)
- Cardiotoxicity Risk with Bortezomib Versus Lenalidomide for Treatment of Multiple Myeloma: A Propensity-Matched Study of 1,128 Patients (2015) (2)
- Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia (2018) (2)
- Outcomes of cardiac resynchronization therapy in patients with chemotherapy‐induced cardiomyopathy (2021) (2)
- How I treat cardiovascular complications in patients with lymphoid malignancies. (2021) (2)
- Sparing of the Cardiac Valves and Left Ventricle using Proton Therapy with ECG-gated CT with Coronary Angiography for the Treatment of Mediastinal Lymphoma (2018) (2)
- Abstract 11675: Global Cardio Oncology Registry: Structure for a Multinational Collaboration (2021) (2)
- New kits on the blot--can we microarray the future of atherosclerosis? (2003) (2)
- Clinical Cardio-Oncology (2016) (2)
- Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer (2021) (2)
- Abstract 14768: Echocardiographic Strain Outcomes of Cardiac Resynchronization Therapy in Patients With Chemotherapy Induced Cardiomyopathy (2020) (1)
- In Reply II-A Differing Opinion on Primary Percutaneous Coronary Intervention in Patients Who Have Had Cancer: Stent Choice in Onco-cardiology Revisited. (2017) (1)
- An artificial intelligence-enabled analysis of ECG changes after androgen deprivation therapy (ADT) for prostate cancer. (2020) (1)
- AN ARTIFICIAL INTELLIGENCE-ENABLED ECG FOR ASSESSING THE RISK OF LEFT VENTRICULAR DYSFUNCTION AMONG CANCER PATIENTS RECEIVING CHEMOTHERAPY (2022) (1)
- Clinical outcomes after fractional flow reserve-guided treatment of oncology patients. (2018) (1)
- Year in cardiovascular medicine: cardio-oncology 2020-21. (2022) (1)
- The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology (2023) (1)
- Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease (2022) (1)
- Large meals and large arteries: is resistin the link? (2006) (1)
- Bridging and spasming. (2012) (1)
- ACUTE CORONARY SYNDROME IN ACTIVE HEMATOLOGICAL MALIGNANCIES: A COHORT STUDY OF 5,300 PATIENTS (2016) (1)
- Assessing Clinical Impact of Myocardial Perfusion Studies: Ischemia or Other Prognostic Indicators? (2014) (1)
- Erratum to arterial events in cancer patients-the case of acute coronary thrombosis. (2019) (1)
- A Comparison of Proton and X-ray Therapy for Coronary Artery Sparing Using ECG-gated CT with Coronary Angiography for Mediastinal Lymphoma (2018) (1)
- Cardiotoxicity assessment in breast cancer patients: is it straining? (2022) (1)
- Risk of QTc interval prolongation among cancer patients treated with tyrosine kinase inhibitors. (2019) (1)
- A classic case of amyloid cardiomyopathy (2012) (1)
- INTRACORONARY IMAGING-GUIDED DISCONTINUATION OF DUAL ANTIPLATELET THERAPY IN STENTED PATIENTS REQUIRING EXPEDITED CANCER TREATMENT (2020) (1)
- P1683 Myocardial bridging is characterized by endothelial dysfunction (2003) (1)
- P5228Epicardial versus endocardial strain and strain rate evaluation in oncological patients undergoing a new radiotherapeutic treatment: proton beam versus photon (x-ray) radiotherapy (2017) (1)
- DOES HIGH DOSE DOXORUBICIN BASED CHEMOTHERAPY INDUCE CARDIOTOXICITY IN PATIENTS WITH SARCOMA? RESULTS FROM A PILOT RETROSPECTIVE STUDY (2018) (0)
- Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era (2019) (0)
- Cardio-oncology: What is the future? (2016) (0)
- Book reviewCoronary Stenting: A Companion to Topol’s Textbook of Interventional Cardiology, edited by Matthew J. Price, 250 pp, with illus, $164, Philadelphia, Elsevier (1-866-896-3331), 2013, ISBN 978-1455707645. (2014) (0)
- Detecting Cardiotoxicity in Cancer Patients Receiving VEGF Inhibitors. (2019) (0)
- Advancing Cardio-Oncology in Asia (2022) (0)
- Chest painduringstem cellinfusionshould be promptlyevaluated in conjunction with cardiology, and spontaneous coronary dissection should be considered in the differential diagnosis, especially in female patients. (2016) (0)
- Bioprosthetic valve monitoring in patients with carcinoid heart disease (2023) (0)
- Determination of Role of Endothelium in Vasoactive Effect of CRP (2002) (0)
- CARDIAC LYMPHOMA MANAGED WITH CAR-T THERAPY (2023) (0)
- Cancer therapeutic drug guide (0)
- ELDERLY PATIENTS PRESENTING WITH STEMI APPEAR TO PRESENT LATER DESPITE TARGETED PROTOCOLS FOR EXPEDITING CARE (2018) (0)
- 1025-45 Preprocedural statin medication reduces small and large periprocedural myocardial injury in patients with stent implantation (2004) (0)
- MAYO MODEL FOR PREDICTING ACUTE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS AFTER CHEST RADIOTHERAPY IN PATIENTS WITH BREAST OR LUNG CANCER (2021) (0)
- Appendix: Drug Guide (2016) (0)
- Risk of Heart Failure after Radiotherapy in Women with HER2+ Breast Cancer Treated with Trastuzumab (2019) (0)
- CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement (2023) (0)
- 100.56 Reclassification of Treatment Strategy With Fractional Flow Reserve in Cancer Patients With Coronary Artery Disease (2019) (0)
- Year Book of Cardiology 2015 : Practicel Update (2016) (0)
- The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Rate Imaging for the Early Detection of Bevacizumab and Sunitinib Mediated Cardiotoxicity (2013) (0)
- IS THERE A RELATIONSHIP BETWEEN MYOCARDIAL PERFUSION AND CARDIAC DYSFUNCTION IN PATIENTS TREATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR THERAPY? A STUDY OF QUANTITATIVE CONTRAST ECHOCARDIOGRAPHY AND STRAIN IMAGING (2015) (0)
- EARLY AND DELAYED CARDIAC COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION AND THE UTILITY OF BASELINE ECHOCARDIOGRAPHY IN RISK STRATIFICATION (2019) (0)
- Cholesterol measurements--update. (1989) (0)
- Systematic review and meta-analysis of definitions and reported incidences of anthracycline cardiotoxicity. (2019) (0)
- 550: CRITICAL ILLNESS COMPLICATIONS OF CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY TREATED IN THE ICU (2020) (0)
- Mitral annular plane systolic excursion and global longitudinal strain for the prediction of cardiotoxicity or heart failure in lymphoma patients treated with anthracycline-based chemotherapy (2022) (0)
- Radiation therapy induces immunosenescence mediated by p90RSK (2022) (0)
- Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. (2016) (0)
- TCT-607 Sex-related differences in fractional flow reserve guided treatment (2013) (0)
- Descriptive evaluation of frequent patient referrals to our cardio-oncology clinic: The Mayo experience. (2020) (0)
- Hypertension and renal disease prevention before cancer therapy (0)
- Abstract 123: The Immunoproteasome Does Not Influence Macrophage Differentiation but Survival of Differentiated Macrophages (2015) (0)
- Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation. (2023) (0)
- Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise (2022) (0)
- Vascular disease during cancer therapy (0)
- Coronary microvascular dysfunction is an independent predictor of developing cancer in patients with non-obstructive coronary artery disease (NOCAD). (2022) (0)
- Retinoid X receptor alpha is a spatiotemporally-specific therapeutic target for doxorubicin-induced cardiomyopathy in adult zebrafish (2018) (0)
- MULTIVESSEL SPONTANEOUS CORONARY ARTERY DISSECTIONS ASSOCIATED WITH ACALABRUTINIB (2023) (0)
- Mortality and major adverse cardiac events in women with breast cancer receiving radiotherapy: a 10-year cohort study of patients and population controls (2022) (0)
- Abstract 5868: Factors associated with exercise participation in patients with breast cancer (2022) (0)
- P1645 The coronary ubiquitin proteasome system is functionally active in the early stage of atherogenesis (2003) (0)
- Safety of trastuzumab in women with HER2+ breast cancer. (2017) (0)
- Editorial commentary: On the evaluation of patients with chest pain: Who are the risk takers? (2017) (0)
- Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL) (2020) (0)
- Cardiovascular screening in long-term Hodgkin lymphoma survivors. (2014) (0)
- Key points of cardio-oncology evaluation before cancer therapy (0)
- Comprar Clinical Cardio-Oncology | J. Herrmann | 9780323442275 | Elsevier España (2016) (0)
- Key points of cardio-oncology evaluation during cancer therapy (0)
- Hypertension and renal disease during anti-cancer therapies (0)
- N-terminal pro-brain natriuretic peptide levels after receipt of anthracycline for breast cancer. (2020) (0)
- Peripheral endothelial function changes during HER2-directed therapy differ based on whether or not a patient receives anthracycline. (2020) (0)
- THE ROLE OF CD38 AS A THERAPEUTIC TARGET FOR PROTECTION AGAINST DOXORUBICIN-INDUCED CARDIOTOXICITY (2023) (0)
- Detection of atrial arrhythmias in DDD pacemaker by automatic interpretation of data analysis A new tool for follow-up (1999) (0)
- Vascular disease prevention: Before cancer therapy (0)
- 1063-59 Preprocedural statin medication reduces the risk for periprocedural myocardial infarctions in patients with stent implantation independent of the cholesterol level (2004) (0)
- Preface: Cardio-oncology: What Do You Know? (2016) (0)
- Vascular disease prevention and management after cancer therapy (0)
- TRASTUZUMAB CARDIOTOXICITY SURVEILLANCE BY ARTIFICIAL INTELLIGENCE-AUGMENTED ELECTROCARDIOGRAPHY IN A MULTI SITE STUDY (2020) (0)
- Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis Molecular Medicine (2007) (0)
- Abstract 10607: Evaluating Diastolic Function by Echocardiography in a Prospective Cohort of Patients with Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL) Who Received Anthracycline-Based Chemotherapy (2021) (0)
- Abstract 5899: Chronic Proteasome Inhibition Leads to Dilative Cardiomyopathy (2008) (0)
- IS SYSTOLIC AND DIASTOLIC FUNCTION INCLUDING GLOBAL LONGITUDINAL STRAIN BY ECHOCARDIOGRAPHY COMPROMISED IN ADULT PATIENTS TREATED WITH CD19 CAR T-CELL THERAPIES FOR HEMATOLOGICAL MALIGNANCIES IN THOSE THAT DEVELOPED CYTOKINE RELEASE SYNDROME? (2023) (0)
- Chapter 22 – Structure and Implementation of Cardio-oncology Care (2016) (0)
- Incidence, Risk Factors, and Outcomes of Early Adverse Cardiac Events (EACE) after Allogeneic Hematopoietic Stem Cell Transplantation Stratified by Conditioning Regimen (2018) (0)
- 1027-189 Chronic endothelin receptor antagonism preserves endothelial function in a transgenic mouse model of alzheimer's disease (2004) (0)
- Basic or comprehensive strain analyses, which variable is better to predict hard endpoints as clinical heart failure in lymphoma patients receiving anthracyclines (2022) (0)
- Hypertension and renal failure prevention and management after cancer therapy (0)
- Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade. (2023) (0)
- Mechanisms of Myocardial Ischemia in Cancer Patients: A State-of-the-Art Review of Obstructive Versus Non-Obstructive Causes (2022) (0)
- IN-HOSPITAL OUTCOMES AMONG COVID-19 PATIENTS WITH CANCER AND CARDIOVASCULAR DISEASE (2021) (0)
- STRESS INDUCED CARDIOMYOPATHY TRIGGERED BY CHEMOTHERAPY: WHEN SHOULD CANCER THERAPY BE RESTARTED? (2017) (0)
- HOME CARDIAC SURVEILLANCE WITH ARTIFICIAL INTELLIGENCE DIGITAL PATIENT MONITORING DURING TREATMENT WITH PERTUZUMAB, TRASTUZUMAB AND HYALURONIDASE-ZZXF FOR HER2-POSITIVE BREAST CANCER (HARRIET): STUDY DESIGN AND RATIONALE (2022) (0)
- Cardiac Masses Discovered by Echocardiogram; What to Do Next? (2023) (0)
- Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (2020) (0)
- Reply: Cancer Patient Risk After Coronary Intervention: Words of Caution in Complicated Patients. (2021) (0)
- Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play (2023) (0)
- Factors Associated With Physical Activity Levels in Patients With Breast Cancer (2022) (0)
- Cardio-oncology : management of cardiovascular toxicity (2019) (0)
- Seeing is believing: new updates on coronary microvascular dysfunction. (2015) (0)
- Current treatment options in oncology , 20 ( 6 ) ISSN 1534-6277 (2019) (0)
- Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer (2018) (0)
- Trigger related outcomes of takotsubo syndrome in a cancer population (2022) (0)
- Key points of cardio-oncology evaluation after cancer therapy (0)
- Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk. (2023) (0)
- Abstract 21004: Relation Between Optimal Medical Therapy Trends on Outcomes in Patients With Peripheral Arterial Disease and Coronary Artery Disease Undergoing Cardiac Catheterization (2017) (0)
- Vascular Toxicity of Tyrosine Kinase Inhibitors: Peripheral Vascular and Coronary Artery Disease (2021) (0)
- The cardio-oncology clinic: Goals, scope, and focus of practice (0)
- Cancer treatment-induced NAD+ depletion in premature senescence and late cardiovascular complications (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Joerg Herrmann?
Joerg Herrmann is affiliated with the following schools:
